Mode
Text Size
Log in / Sign up
N/A Completed N=24 Diagnostic

Contrast ICE for Myocardial Scar in VT Ablations

Ventricular Tachycardia · Ischemic Cardiomyopathy
Source: ClinicalTrials.gov NCT03212326 ↗
Enrolled (actual)
24
Serious AEs
0.0%
Results posted
May 2019
Primary outcomePrimary: Number of Subjects With Myocardial Scar on Echo and Voltage Maps — 20 Participants

Summary

There is a high correlation between scar areas identified by contrast-enhanced ICE and scar areas identified by conventional electroanatomic mapping. Therefore, the investigators will assess the utility of contrast-enhanced ICE to identify and localize myocardial scar real-time during VT ablation procedures.

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Subjects With Myocardial Scar on Echo and Voltage Maps
20
SECONDARY
Number of Subjects With Ventricular Tachycardia Mapped
20

Eligibility Criteria

Inclusion Criteria

  • Subject is 18 years of age or older
  • Subject is undergoing catheter ablation of likely reentrant VT
  • Planned use of intracardiac echocardiography (ICE)
  • Subject is willing to sign and date the study informed consent form

Exclusion Criteria

  • Contraindication to Perflutren (Optison) echo contrast
  • Known right-to-left, bidirectional, or transient right-to-left cardiac shunts
  • Known hypersensitivity to Perflutren, blood, blood products or albumin
  • Subject has medical condition that would limit study participation (as per MD discretion)
  • Subject is pregnant
  • Inability to give informed consent
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03212326). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search